{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:54:55Z","timestamp":1793199295351,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1161571"],"award-info":[{"award-number":["GNT1161571"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins & Other Lipid Mediators"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.prostaglandins.2024.106943","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T16:35:26Z","timestamp":1734453326000},"page":"106943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A high seizure burden increases brain concentrations of specialized pro-resolving mediators in the Scn1a mouse model of Dravet syndrome"],"prefix":"10.1016","volume":"176","author":[{"given":"Ka Lai","family":"Yip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cilla","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon C.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2024.106943_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1096\/fj.06-7227rev","article-title":"Resolution of inflammation: state of the art, definitions and terms","volume":"21","author":"Serhan","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bbi.2011.03.018","article-title":"IL-1 receptor\/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures","volume":"25","author":"Vezzani","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib5","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib6","doi-asserted-by":"crossref","DOI":"10.1542\/peds.102.5.e51","article-title":"Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses to prevent febrile seizure recurrences","volume":"102","author":"van Stuijvenberg","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bcp.13048","article-title":"Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective","volume":"82","author":"Patrono","year":"2016","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.immunol.25.022106.141647","article-title":"Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways","volume":"25","author":"Serhan","year":"2007","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.smim.2015.03.014","article-title":"The resolution of inflammation: Principles and challenges","volume":"27","author":"Headland","year":"2015","journal-title":"Semin Immunol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib11","unstructured":"Resolvyx Pharmaceuticals Inc. Safety and efficacy study of RX-10045 on the signs and symptoms of dry eye. Available at: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00799552\u3009."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib12","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1528-1167.2011.03081.x","article-title":"The omega-3 fatty acid-derived neuroprotectin D1 limits hippocampal hyperexcitability and seizure susceptibility in kindling epileptogenesis","volume":"52","author":"Musto","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-8993(99)01997-6","article-title":"Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation","volume":"846","author":"Xiao","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainres.2013.09.004","article-title":"Selective reduction of excitatory hippocampal sharp waves by docosahexaenoic acid and its methyl ester analog ex-vivo","volume":"1537","author":"Taha","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib15","first-page":"3130","article-title":"n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis","volume":"141","author":"Frigerio","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116543","article-title":"Hippocampal neuro-networks and dendritic spine perturbations in epileptogenesis are attenuated by neuroprotectin d1","volume":"10","author":"Musto","year":"2015","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106943_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/brain\/awm002","article-title":"The spectrum of SCN1A-related infantile epileptic encephalopathies","volume":"130","author":"Harkin","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106842","article-title":"Adolescent behavioral abnormalities in a Scn1a(+\/-) mouse model of Dravet syndrome","volume":"103","author":"Bahceci","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2024.106836","article-title":"A high seizure burden increases several prostaglandin species in the hippocampus of a Scn1a(+\/-) mouse model of Dravet syndrome","volume":"172","author":"Zhou","year":"2024","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2014.01.006","article-title":"Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice","volume":"65","author":"Mistry","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/gbb.12099","article-title":"Mapping genetic modifiers of survival in a mouse model of Dravet syndrome","volume":"13","author":"Miller","year":"2014","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/acn3.413","article-title":"Screening of conventional anticonvulsants in a genetic mouse model of epilepsy","volume":"4","author":"Hawkins","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib24","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.expneurol.2017.03.026","article-title":"Early-life febrile seizures worsen adult phenotypes in Scn1a mutants","volume":"293","author":"Dutton","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchromb.2013.06.014","article-title":"LC-MS\/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites","volume":"932","author":"Le Faouder","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0006-8993(90)90579-Z","article-title":"Cysteinyl-leukotriene production during limbic seizures triggered by kainic acid","volume":"515","author":"Simmet","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuroscience.2014.07.058","article-title":"Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction","volume":"277","author":"Lenz","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.plefa.2011.04.003","article-title":"Modulation of leukotriene D4 attenuates the development of seizures in mice","volume":"85","author":"Rehni","year":"2011","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib30","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.4049\/jimmunol.1101305","article-title":"Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice","volume":"187","author":"Bento","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib31","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.40001","article-title":"Targeting the D series resolvin receptor system for the treatment of osteoarthritis pain","volume":"69","author":"Huang","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib32","doi-asserted-by":"crossref","first-page":"14677","DOI":"10.1074\/jbc.M300218200","article-title":"Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation","volume":"278","author":"Hong","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nm.3911","article-title":"Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections","volume":"21","author":"Dalli","year":"2015","journal-title":"Nat. Med"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.chembiol.2006.09.011","article-title":"Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis","volume":"13","author":"Tjonahen","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.706","article-title":"Downregulated formyl peptide receptor 2 expression in the epileptogenic foci of patients with focal cortical dysplasia type IIb and tuberous sclerosis complex","volume":"10","author":"Huang","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib36","doi-asserted-by":"crossref","unstructured":"Xu Z.Z., Zhang L., Liu T., Park J.Y., Berta T., Yang R., et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions Nat Med. 2010;16:592-597, 591p following 597.","DOI":"10.1038\/nm.2123"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib37","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood.2018886317","article-title":"Resolvin D4 attenuates the severity of pathological thrombosis in mice","volume":"134","author":"Cherpokova","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib38","doi-asserted-by":"crossref","first-page":"E4753","DOI":"10.1073\/pnas.1415006111","article-title":"Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection","volume":"111","author":"Dalli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.immuni.2016.12.009","article-title":"Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution","volume":"46","author":"Dalli","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib40","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202101815R","article-title":"Lipid mediator n-3 docosapentaenoic acid-derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a G-protein-coupled receptor","volume":"36","author":"Mikroulis","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib41","article-title":"Maresin: macrophage mediator for resolving inflammation and bridging tissue regeneration-a system-based preclinical systematic review","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12974-022-02386-1","article-title":"Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis","volume":"19","author":"Sanchez-Fernandez","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12974-022-02405-1","article-title":"Maresin 1 promotes nerve regeneration and alleviates neuropathic pain after nerve injury","volume":"19","author":"Wei","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.prostaglandins.2024.106943_bib44","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1038\/s41380-021-01160-8","article-title":"Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis","volume":"26","author":"Borsini","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.prostaglandins.2024.106943_bib45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41386-022-01527-7","article-title":"Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators","volume":"48","author":"Lamon-Fava","year":"2023","journal-title":"Neuropsychopharmacology"}],"container-title":["Prostaglandins & Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882324001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882324001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:56:55Z","timestamp":1737323815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882324001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":45,"alternative-id":["S1098882324001370"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2024.106943","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A high seizure burden increases brain concentrations of specialized pro-resolving mediators in the Scn1a+\/- mouse model of Dravet syndrome","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2024.106943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106943"}}